{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:44:07Z","timestamp":1793339047043,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Aging Clin Exp Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Chronic kidney disease (CKD) and sarcopenia are independently associated with adverse cardiovascular and mortality outcomes. However, the combined impact of CKD and sarcopenia remains poorly understood. To evaluate the combined effects of CKD and sarcopenia on cardiovascular disease (CVD) and mortality risks in a large population-based cohort.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We analyzed data from 477,380 participants in the UK Biobank, categorized into four groups based on the presence or absence of CKD and sarcopenia: Non-CKD Non-Sarcopenia, Non-CKD Sarcopenia, CKD Non-Sarcopenia, and CKD Sarcopenia. Cox proportional hazards models estimated hazard ratios (HRs) with 95% confidence intervals (CIs) for CVD and mortality outcomes. Kaplan-Meier survival analyses compared event-free survival across the groups.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Participants with both CKD and sarcopenia exhibited the highest risks across all outcomes compared to those without either condition. For stroke, the adjusted HR was 2.17 (95% CI: 1.65\u20132.86), significantly higher than CKD alone (HR: 1.69, 95% CI: 1.47\u20131.94) or sarcopenia alone (HR: 1.28, 95% CI: 1.03\u20131.59). Similar trends were observed for coronary artery disease (CAD) and heart failure (HF), with HRs of 1.53 (95% CI: 1.38\u20131.69) and 2.22 (95% CI: 1.99\u20132.47), respectively, in the CKD-sarcopenia group. The coexistence of CKD and sarcopenia was also associated with significantly elevated all-cause mortality (HR: 2.59, 95% CI: 2.17\u20133.09) and cardiovascular-specific mortality (HR: 4.08, 95% CI: 2.95\u20135.66).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The coexistence of CKD and sarcopenia significantly amplifies the risks of CVD and mortality, highlighting the need for integrated management strategies to address this high-risk population. Early detection and tailored interventions targeting these dual risk factors may mitigate their compounded burden and improve clinical outcomes.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s40520-025-03003-w","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T09:58:31Z","timestamp":1742205511000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Association between the coexistence of chronic kidney disease and sarcopenia with cardiovascular disease and mortality"],"prefix":"10.1007","volume":"37","author":[{"given":"Lijun","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangliang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyu","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,17]]},"reference":[{"key":"3003_CR1","doi-asserted-by":"publisher","first-page":"111094","DOI":"10.1016\/j.diabres.2024.111094","volume":"208","author":"P Zhang","year":"2024","unstructured":"Zhang P, Zhang Z, Zhong J, Zheng X, Zhou J, Sun W (2024) Cardiovascular diseases consequences of type 1, type 2 diabetes mellitus and glycemic traits: A Mendelian randomization study. Diabetes Res Clin Pract 208:111094","journal-title":"Diabetes Res Clin Pract"},{"issue":"9889","key":"3003_CR2","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","volume":"382","author":"RT Gansevoort","year":"2013","unstructured":"Gansevoort RT, Correa-Rotter R, Hemmelgarn BR et al (2013) Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 382(9889):339\u2013352","journal-title":"Lancet"},{"issue":"20","key":"3003_CR3","first-page":"1534","volume":"147","author":"AA Damluji","year":"2023","unstructured":"Damluji AA, Alfaraidhy M, AlHajri N et al (2023) Sarcopenia Cardiovasc Dis Circulation 147(20):1534\u20131553","journal-title":"Sarcopenia Cardiovasc Dis Circulation"},{"key":"3003_CR4","doi-asserted-by":"crossref","unstructured":"Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY (2008) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization [published correction appears in N Engl J Med.;18(4):4]. N Engl J Med. 2004;351(13):1296\u20131305","DOI":"10.1056\/NEJMoa041031"},{"key":"3003_CR5","doi-asserted-by":"publisher","first-page":"155533","DOI":"10.1016\/j.metabol.2023.155533","volume":"144","author":"S Yuan","year":"2023","unstructured":"Yuan S, Larsson SC (2023) Epidemiology of sarcopenia: prevalence, risk factors, and consequences. Metabolism 144:155533","journal-title":"Metabolism"},{"issue":"2","key":"3003_CR6","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1002\/jcsm.13425","volume":"15","author":"MP Duarte","year":"2024","unstructured":"Duarte MP, Almeida LS, Neri SGR et al (2024) Prevalence of sarcopenia in patients with chronic kidney disease: a global systematic review and meta-analysis. J Cachexia Sarcopenia Muscle 15(2):501\u2013512","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"19","key":"3003_CR7","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.3390\/nu14194077","volume":"14","author":"W Wathanavasin","year":"2022","unstructured":"Wathanavasin W, Banjongjit A, Avihingsanon Y et al (2022) Prevalence of sarcopenia and its impact on cardiovascular events and mortality among Dialysis patients: A systematic review and Meta-Analysis. Nutrients 14(19):4077","journal-title":"Nutrients"},{"issue":"5","key":"3003_CR8","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1002\/jcsm.13525","volume":"15","author":"P Zhang","year":"2024","unstructured":"Zhang P, Zhong J, Liu X, Sun W (2024) The association between dynamic changes in vitamin D and frailty alterations: A prospective analysis of UK biobank participants. J Cachexia Sarcopenia Muscle 15(5):1722\u20131732","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"3003_CR9","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1093\/ageing\/afz046","volume":"48","author":"AJ Cruz-Jentoft","year":"2019","unstructured":"Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruy\u00e8re O, Cederholm T et al (2019) Sarcopenia: revised European consensus on defnition and diagnosis. Age Ageing 48:601","journal-title":"Age Ageing"},{"issue":"2","key":"3003_CR10","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1152\/jappl.2000.89.2.465","volume":"89","author":"I Janssen","year":"2000","unstructured":"Janssen I, Heymsfield SB, Baumgartner RN, Ross R (2000) Estimation of skeletal muscle mass by bioelectrical impedance analysis. J Appl Physiol (1985) 89(2):465\u2013471","journal-title":"J Appl Physiol (1985)"},{"issue":"19","key":"3003_CR11","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","volume":"385","author":"LA Inker","year":"2021","unstructured":"Inker LA, Eneanya ND, Coresh J et al (2021) New Creatinine- and Cystatin C-Based equations to estimate GFR without race. N Engl J Med 385(19):1737\u20131749","journal-title":"N Engl J Med"},{"issue":"10075","key":"3003_CR12","first-page":"1238","volume":"389","author":"AC Webster","year":"2017","unstructured":"Webster AC, Nagler EV, Morton RL, Masson P (2017) Chronic Kidney Disease Lancet 389(10075):1238\u20131252","journal-title":"Chronic Kidney Disease Lancet"},{"issue":"12","key":"3003_CR13","doi-asserted-by":"publisher","first-page":"e576","DOI":"10.1016\/S2468-2667(18)30200-7","volume":"3","author":"HME Foster","year":"2018","unstructured":"Foster HME, Celis-Morales CA, Nicholl BI et al (2018) The effect of socioeconomic deprivation on the association between an extended measurement of unhealthy lifestyle factors and health outcomes: a prospective analysis of the UK biobank cohort. Lancet Public Health 3(12):e576\u2013e585","journal-title":"Lancet Public Health"},{"issue":"4","key":"3003_CR14","doi-asserted-by":"publisher","first-page":"352","DOI":"10.4239\/wjd.v14.i4.352","volume":"14","author":"WR Lin","year":"2023","unstructured":"Lin WR, Liu KH, Ling TC, Wang MC, Lin WH (2023) Role of antidiabetic agents in type 2 diabetes patients with chronic kidney disease. World J Diabetes 14(4):352\u2013363","journal-title":"World J Diabetes"},{"issue":"5","key":"3003_CR15","doi-asserted-by":"publisher","first-page":"982","DOI":"10.3390\/nu14050982","volume":"14","author":"A de Sire","year":"2022","unstructured":"de Sire A, Ferrillo M, Lippi L et al (2022) Sarcopenic dysphagia, malnutrition, and oral frailty in elderly: A comprehensive review. Nutrients 14(5):982","journal-title":"Nutrients"},{"issue":"4","key":"3003_CR16","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1097\/TP.0000000000000968","volume":"100","author":"MS Van Sandwijk","year":"2016","unstructured":"Van Sandwijk MS, Ten Berge IJ, Majoie CB et al (2016) Cognitive changes in chronic kidney disease and after transplantation. Transplantation 100(4):734\u2013742","journal-title":"Transplantation"},{"key":"3003_CR17","doi-asserted-by":"publisher","first-page":"1241943","DOI":"10.3389\/fcvm.2023.1241943","volume":"10","author":"R Larivi\u00e8re","year":"2023","unstructured":"Larivi\u00e8re R, Ung RV, Picard S, Richard DE, Mac-Way F, Agharazii M (2023) Antihypertensive treatment with hydrochlorothiazide-hydralazine combination aggravates medial vascular calcification in CKD rats with mineral bone disorder. Front Cardiovasc Med 10:1241943","journal-title":"Front Cardiovasc Med"},{"key":"3003_CR18","doi-asserted-by":"publisher","first-page":"1427692","DOI":"10.3389\/fneur.2024.1427692","volume":"15","author":"FQ Meng","year":"2024","unstructured":"Meng FQ, Zhang Y, Bai XX, Kong FL, Li FE (2024) Ischemic stroke and sarcopenia have an asymmetric bidirectional relationship based on a two-sample Mendelian randomization study. Front Neurol 15:1427692","journal-title":"Front Neurol"},{"issue":"1","key":"3003_CR19","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1080\/0886022X.2022.2142140","volume":"44","author":"SM Lee","year":"2022","unstructured":"Lee SM, Jeong EG, Jeong YI, Rha SH, Kim SE, An WS (2022) Omega-3 fatty acid and menaquinone-7 combination are helpful for aortic calcification prevention, reducing osteoclast area of bone and Fox0 expression of muscle in uremic rats. Ren Fail 44(1):1873\u20131885","journal-title":"Ren Fail"},{"issue":"1","key":"3003_CR20","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1080\/07853890.2022.2057581","volume":"54","author":"A Bailey","year":"2022","unstructured":"Bailey A, Brody R, Sackey J, Parrott JS, Peters E, Byham-Gray L (2022) Current methods for developing predictive energy equations in maintenance dialysis are imprecise. Ann Med 54(1):909\u2013920","journal-title":"Ann Med"},{"key":"3003_CR21","doi-asserted-by":"publisher","first-page":"205435811775361","DOI":"10.1177\/2054358117753615","volume":"5","author":"CJ Bohm","year":"2018","unstructured":"Bohm CJ, Storsley LJ, Hiebert BM et al (2018) Impact of exercise counseling on physical function in chronic kidney disease: an observational study. Can J Kidney Health Dis 5:2054358117753615","journal-title":"Can J Kidney Health Dis"},{"issue":"2","key":"3003_CR22","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1002\/2211-5463.13083","volume":"11","author":"T Ishii","year":"2021","unstructured":"Ishii T, Kumagae T, Wakui H et al (2021) Tissue Xanthine oxidoreductase activity in a mouse model of aristolochic acid nephropathy. FEBS Open Bio 11(2):507\u2013518","journal-title":"FEBS Open Bio"},{"issue":"4","key":"3003_CR23","doi-asserted-by":"publisher","first-page":"192","DOI":"10.4103\/tcmj.tcmj_123_17","volume":"29","author":"JP Tsai","year":"2017","unstructured":"Tsai JP (2017) The association of serum leptin levels with metabolic diseases. Tzu Chi Med J 29(4):192\u2013196","journal-title":"Tzu Chi Med J"},{"issue":"15","key":"3003_CR24","doi-asserted-by":"publisher","first-page":"e35587","DOI":"10.1016\/j.heliyon.2024.e35587","volume":"10","author":"D Wu","year":"2024","unstructured":"Wu D, Cao J, Lin Y et al (2024) Relationship between creatinine-cystatin C ratio and all-cause mortality in hospitalized patients with COVID-19: A prospective study in China. Heliyon 10(15):e35587","journal-title":"Heliyon"},{"issue":"1","key":"3003_CR25","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1053\/j.ajkd.2011.10.008","volume":"59","author":"KL Johansen","year":"2012","unstructured":"Johansen KL, Painter P (2012) Exercise in individuals with CKD. Am J Kidney Dis 59(1):126\u2013134","journal-title":"Am J Kidney Dis"}],"container-title":["Aging Clinical and Experimental Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-025-03003-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40520-025-03003-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-025-03003-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T09:58:34Z","timestamp":1742205514000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40520-025-03003-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,17]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3003"],"URL":"https:\/\/doi.org\/10.1007\/s40520-025-03003-w","relation":{},"ISSN":["1720-8319"],"issn-type":[{"value":"1720-8319","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,17]]},"assertion":[{"value":"5 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"92"}}